Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience
Authors:
- 6 September 2007
- journal article
- review article
- Published by Springer Nature in Angiogenesis
- Vol. 10 (4) , 243-258
Abstract
The idea of a therapeutic modality aimed at ‘starving’ a tissue of blood vessels, and consequentially of oxygen and nutrients, was born from the concept that blood vessel formation (angiogenesis) is central to the progression and maintenance of diseases which involve tissue expansion/invasion. In the first instance, solid malignancies were the target for anti-angiogenic treatments, with colorectal cancer being the first disease for which an angiogenesis inhibitor—anti-vascular endothelial growth factor antibody bevacizumab—was approved in 2004. Our understanding of the pathogenesis of rheumatoid arthritis (RA) has lead to many parallels being drawn between this chronic inflammatory disease and solid tumours, in that both involve tissue expansion, invasion, expression of cytokines and growth factors and areas of hypoxia/hypoperfusion. As a result, angiogenesis blockade has been touted as a possible treatment for RA. The lessons learnt during the progression of eventually successful therapies such as bevacizumab should undoubtedly guide us in the future development of comparable treatments for RA.Keywords
This publication has 159 references indexed in Scilit:
- Vascular endothelial growth factor: Biology and therapeutic applicationsThe International Journal of Biochemistry & Cell Biology, 2007
- Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblastsProceedings of the National Academy of Sciences, 2007
- Effect of anti-TNFα treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritisLife Sciences, 2006
- The transcription factors hypoxia‐inducible factor 1α and Ets‐1 colocalize in the hypoxic synovium of inflamed joints in adjuvant‐induced arthritisArthritis & Rheumatism, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Hypoxia as a target for combined modality treatmentsEuropean Journal of Cancer, 2002
- Neutralization of Vascular Endothelial Growth Factor Prevents Collagen-Induced Arthritis and Ameliorates Established Disease in MiceBiochemical and Biophysical Research Communications, 2001
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971
- ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESISJournal of Experimental Medicine, 1971